- Pioneering next-level sample processing with connectivity,
simplicity, and unmatched flexibility
- Building on the success of EZ1 technology, three versions offer
application area tailored value
- Integration with QIAsphere digital infrastructure allows for
optimized lab productivity
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the upcoming launch of the EZ2 Connect product line, a
next-level automated sample-processing platform whose simplicity,
flexibility and speed will benefit biomedical research, forensics
and clinical diagnostics.
The EZ2 Connect instruments use pre-filled cartridges and
magnetic bead technology to process up to 24 samples in parallel in
as little as 20 minutes, ensuring process safety and efficiency of
nucleic acid extraction. The new platform builds on QIAGEN’s
groundbreaking EZ1 instrument line, which set new standards in the
automation of sample preparation and sample-data management and has
seen more than 4,500 devices installed worldwide at the end of
2020.
“Expanding on the strength of our sample-processing portfolio,
we are paving the way to a new era of laboratory automation,” said
Thomas Schweins, Senior Vice President, Business Area Life Sciences
of QIAGEN. ”The EZ2 Connect platform makes standardized and
efficient nucleic acid purification accessible for any lab -
without the need for specialized training or previous experience
with automation platforms, while providing a new level of
connectivity for ease-of-use and reliability of results.”
The EZ2 Connect platform has a broad range of application areas,
and will be tailored to three different key versions. The EZ2
Connect for use in research and pharmaceutical laboratory and the
EZ2 Connect Fx for use in forensics and human identification (HID)
will be launched in July. The release of the EZ2 Connect MDx for
use in molecular diagnostic workflows is planned for early 2022,
with regulatory approval in the U.S., the European Union and other
markets worldwide.
Addressing a wide range of sample types and applications for
biomedical research, the EZ2 Connect comes with an elaborate kit
portfolio. In-tip separation, onboard heating and reagent
pipetting, as well as large volume capabilities enable an
unprecedented level of benchtop automation. With new approaches for
cell free circulating DNA (cfDNA) and nucleic acid extraction from
a range of sample types such as FFPE, EZ2 Connect catalyzes
analytical quality, a valuable tool for example in cancer
research.
The EZ2 Connect Fx is tailored to Human ID and forensics
customer requirements, ensuring performance, process safety and
reliability. It was designed and developed on the experiences and
user feedback of the EZ1’s exceptional success in the HID market
and offers a failure-safe method to isolate DNA even from smallest
traces with highest efficiency. Increased capacity, full
traceability, and maximum sample integrity allow labs to stand
ready 24/7.
The EZ2 Connect MDx will address the challenges of medium
throughput clinical diagnostics labs: dealing with fluctuating
numbers of sample, large variety of sample types and quality, and
less experienced staff. A single-use cartridge per sample and easy
push-button operation minimizes the risk of sampling errors.
The EZ2 Connect platform complements QIAGEN’s leading offering
of automation solutions including the QIAcube Connect and the
QIAsymphony. The QIAcube Connect platform allows for a seamless
transfer of QIAGENs wide range of manual spin column protocols to
flexible and medium throughput automation, with the dedicated
QIAcube Connect MDx version for molecular diagnostics
workflows.
At the end of 2020, more than 9,800 QIAcube platform had been
cumulatively placed with customers worldwide. The QIAsymphony
provides fully automated high throughput with features such as
continuous loading and primary tube handling, and had a cumulative
installed base of over 2,900 systems at the end of 2020.
The newly introduced EZ2 Connect platform allows for medium- to
high-throughput sample processing, combining flexibility with
maximum process safety in dedicated instrument versions tailored to
the individual needs of QIAGEN’s diverse customer base.
The new versions also allow for connection to QIAsphere, a
digital laboratory ecosystem that enables additional remote
features like instrument management and real-time status reporting.
As a result, EZ2 Connect enables optimization of workflows and
greater lab productivity with the next level of daily lab routine
automation.
For more information about the EZ2 Connect platform, please
visit https://www.qiagen.com/us/clp/ez2-connect-updates or see the
product video at
https://www.youtube.com/watch?v=RL5ao-mLXdQ&ab_channel=QIAGEN
More information on QIAGEN can be found at www.qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of December 31, 2020, QIAGEN
employed approximately 5,600 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, including those products used in the response to
the COVID-19 pandemic, timing for launch and development, marketing
and/or regulatory approvals, financial and operational outlook,
growth and expansion, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses; actions of governments, global or regional economic
developments, weather or transportation delays, natural disasters,
political or public health crises, including the breadth and
duration of the COVID-19 pandemic and its impact on the demand for
our products and other aspects of our business, or other force
majeure events; as well as the possibility that expected benefits
related to recent or pending acquisitions may not materialize as
expected; and the other factors discussed under the heading “Risk
Factors” contained in Item 3 of our most recent Annual Report on
Form 20-F. For further information, please refer to the discussions
in reports that QIAGEN has filed with, or furnished to, the U.S.
Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429006087/en/
QIAGEN Investor Relations John Gilardi +49 2103 29
11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public
Relations Thomas Theuringer +49 2103 29 11826 Robert Reitze +49
2103 29 11676 e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024